U.S. Markets open in 7 hrs 50 mins

How Acadia Pharmaceuticals Is Positioned Financially

Daniel Collins
How Acadia Pharmaceuticals Is Positioned Financially

Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.